Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Mass Vaccination Against Polio

Mass Vaccination Against Polio The Introduction of Oral Vaccine Although the introduction and immediate widespread use of inactivated polio vaccine (IPV) in 1955 was accompanied by an abrupt decline in the reported number of cases of poliomyelitis in the United States, there was considerable excitement in the late 1950s about the impending availability of attenuated live (oral) poliovirus vaccine (OPV).1-3 This excitement stemmed both from anticipated advantages of OPV and from some disappointment with the performance of IPV. The anticipated advantages of OPV included its potential to induce effective and long-lasting protection after only one dose, obviating the need for boosters, its ability to pass to contacts of vaccinees, thereby extending the effects of the vaccine beyond those directly vaccinated, and the fact that the protection induced embraces both infection and disease. The disappointment with IPV resulted from the fact that, after a record low of 2,499 cases of paralytic poliomyelitis in 1957, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Mass Vaccination Against Polio

JAMA , Volume 251 (22) – Jun 8, 1984

Loading next page...
 
/lp/american-medical-association/mass-vaccination-against-polio-uRzDCgag0b

References (2)

Publisher
American Medical Association
Copyright
Copyright © 1984 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1984.03340460072029
Publisher site
See Article on Publisher Site

Abstract

The Introduction of Oral Vaccine Although the introduction and immediate widespread use of inactivated polio vaccine (IPV) in 1955 was accompanied by an abrupt decline in the reported number of cases of poliomyelitis in the United States, there was considerable excitement in the late 1950s about the impending availability of attenuated live (oral) poliovirus vaccine (OPV).1-3 This excitement stemmed both from anticipated advantages of OPV and from some disappointment with the performance of IPV. The anticipated advantages of OPV included its potential to induce effective and long-lasting protection after only one dose, obviating the need for boosters, its ability to pass to contacts of vaccinees, thereby extending the effects of the vaccine beyond those directly vaccinated, and the fact that the protection induced embraces both infection and disease. The disappointment with IPV resulted from the fact that, after a record low of 2,499 cases of paralytic poliomyelitis in 1957,

Journal

JAMAAmerican Medical Association

Published: Jun 8, 1984

There are no references for this article.